01:02 PM EDT, 03/18/2024 (MT Newswires) -- Syndax Pharmaceuticals ( SNDX ) said Monday that Steven Closter has succeeded Steve Sabus as chief commercial officer, effective immediately.

Sabus is leaving for "personal reasons," the company said.

Previously, Closter held several positions at Sunovion Pharmaceuticals, according to Syndax.

Syndax shares were down 5.1% in recent trading.

Price: 22.32, Change: -1.20, Percent Change: -5.06